nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2007 | Editorial

PET/CT in head and neck cancer

verfasst von: Liselotte Højgaard, Lena Specht

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Excerpt

Head and neck cancer is the third most frequent cancer worldwide, with 500,000 new cases every year [1]. It is a heterogeneous group of neoplasms arising in the upper aerodigestive tract with different pathophysiologies, histologies and staging paradigms [2]. PET/CT is emerging as the “method of choice” for diagnosis in head and neck cancer [3], and nuclear medicine physicians may regard this diagnostic entity as a rather simple challenge: the cancer, the large nodes and the metastases are often clearly visible on FDG PET/CT and we can just describe what we see and regard the case as closed. …

Hermans R. Tumours of the pharynx, tongue and mouth. In: Husband JE, Reznek RH, editors. Imaging in oncology, 2nd edn. London: Taylor & Francis, 2004.

Macapinlac HH. Head, neck, thyroid. In: Wahl RL, editor. Principles and practice of positron emission tomgraphy. Philadelphia: Lippincott, Williams & Wilkins; 2002; p. 157–65.

Frank SJ, Caho KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumour staging and radiation therapy planning. Nat Clin Pract Oncol 2005;2(10):526–33.PubMedCrossRef

Kristensen CA, Kjær-Kristoffersen F, Sapru W, Berthelsen AK, Loft A, Specht L. Nasopharyngeal carcinoma. Treatment planning with IMRT or conformal 3D-radiotherapy. Acta Oncol 2007;in press.

Borgwardt L, Larsen HJ, Pedersen K, Hojgaard L. Practical use and implementation of PET in children in a hospital PET center. Eur J Nucl Med Mol Imaging 2003;30:1389–97.PubMedCrossRef

Frank SJ, Chao KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumour staging and radiation therapy planning. Nat Clin Pract Oncol 2005;2:526–33.PubMedCrossRef

Chen YK, Su CT, Ding HJ, Chi KH, Liang JA, Shen YY, et al. Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Rese 2006;26:1471–7.

Ng SH, Yen TC, Chang JT, Chan SC, Ko SF, Wang HM, et al. Prospective study of [¹⁸F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 2006;24:4371–6.PubMedCrossRef

Gourin CG, Williams HT, Seabolt WN, Herdman AV, Howington JW, Terris DJ. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006;116:705–10.PubMedCrossRef

10.

Schoder H, Carlson DL, Kraus DH, Stambuk HE, Gonen M, Erdi YE, et al.¹⁸F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755–62.PubMed

11.

Bilde A, Von Buchwald C, Mortensen J, Marving J, Therkildsen MH, Kirkegaard J, et al. The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. Acta Otolaryngol 2006;126:1096–103.PubMedCrossRef

12.

Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Hojgaard L, et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 2006;33:697–701.PubMedCrossRef

13.

Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, et al. Unknown primary tumours: detection wtih dual-modality PET/CT—initial experience. Radiology 2005;234:227–34.PubMedCrossRef

14.

Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Toso S, et al. Role of ¹⁸F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005;32:589–92.PubMedCrossRef

15.

Zimmer LA, Snyderman C, Fukui MB, Blodgett T, McCook B, Townsend DW, et al. The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience. Ear Nose Throat J 2005;84:104, 106, 108–10.

16.

Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006;65:1315–22.PubMedCrossRef

17.

Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132:12–6.PubMedCrossRef

18.

Gordin A, Daitzchman M, Doweck I, Yefremov N, Golz A, Keidar Z, et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope 2006;116:273–8.PubMedCrossRef

19.

Iagaru A, Masamed R, Singer PA, Conti PS. 2-Deoxy-2-[¹⁸F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. Mol Imaging Biol 2006;8:309–14.PubMedCrossRef

20.

Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Højgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1167–75.PubMedCrossRef

21.

Daisne J-F, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93–100.PubMedCrossRef

22.

Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD, et al. Initial experience of FDG-PET/CT guided IMRT of head and neck carcinoma. Int J Radiat Oncol Biol Phys 2006;65:143–51.PubMedCrossRef

23.

Riegel AC, Berson AM, Destian S, NG T, Tena LB, Mitnick RJ, et al. Variability of gross tumour volume delineation in head and neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys 2006;65:726–32.PubMed

24.

Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853–63.PubMedCrossRef

25.

Buus S, Grau C, Munk OL, Bender D, Jensen K, Keiding S.¹¹C-methionine PET, a novel method for measuring regional salivary gland function after radiotherapy of head and neck cancer. Radiother Oncol 2004;73:289–96.PubMedCrossRef

26.

Tunis S. Clinical applications of PET and PET/CT under NOPR expanded coverage. http://www.CMS.org.

27.

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumour oxygenation in 397 head and neck tumours after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18–24.PubMedCrossRef

28.

Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:44–53.PubMedCrossRef

29.

Zimny M, Gagel B, Dimartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG—a marker of tumour hypoxia? A comparison with [¹⁸F]fluoromisonidazole and pO₂-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006;33:1426–31.PubMedCrossRef

30.

Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic¹⁸F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005;5:152.PubMedCrossRef

31.

Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [¹⁸F]-misonidazole positron emission tomography-detected tumour hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study. J Clin Oncol 2006;24:2098–104.PubMedCrossRef

32.

Myerson RJ, Singh AK, Bigott HM, Cha B, Engelbach JA, Kim J, et al. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning. Int J Hyperthermia 2006;22:93–115.PubMedCrossRef

33.

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoural differences in hypoxia selectivity of the PET imaging agent⁶⁴Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006;47:989–98.PubMed

34.

Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181:483–99.PubMedCrossRef

35.

Parodi K, Bortfeld T. A filtering approach based on Gaussian-powerlaw convolutions for local PET verification of proton radiotherapy. Phys Med Biol 2006;51:1991–2009.PubMedCrossRef

36.

Ponisch F, Parodi K, Hasch BG, Enghardt W. The modelling of positron emitter production and PET imaging during carbon ion therapy. Phys Med Biol 2004;49:5217–32.PubMedCrossRef

Titel: PET/CT in head and neck cancer
verfasst von: Liselotte Højgaard
Lena Specht
Publikationsdatum: 01.09.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0373-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2007

Regional CBF changes in Parkinson’s disease: a correlation with motor dysfunction

Simple and highly efficient synthesis of 3′-deoxy-3′-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies

Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma

Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer’s disease using FDG-PET and 3D-SSP

Administering radioiodine treatment; alternative to nuclear medicine prescribing